Álvaro Rodríguez-Lescure

Author

Hospital General Universitario de Elche ORCID

Also Known As

A Rodriguez-Lescure, A Rodríguez-Lescure, A. Rodriguez-Lescure, A. Rodríguez-Lescure, Alvaro Rodriguez-Lescure, Alvaro Rodriguez‐Lescure, Alvaro Rodríguez-Lescure, Ayala De La Peña, F, Á Rodríguez-Lescure, Perou, Charles

139

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Hospital General Universitario de Elche Hospital Universitario Virgen del Rocío Hospital General Universitario Gregorio Marañón GEICAM – Spanish Breast Cancer Group Hospital Clínico San Carlos

ÁR

About

Álvaro Rodríguez-Lescure is an author at Hospital General Universitario de Elche specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	983
2	Health Sciences	3	3	99
3	Cell Biology	2	2	58
4	Engineering	1	1	18
5	Hepatology	1	1	54

Álvaro Rodríguez-Lescure

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Docetaxel for Node-Positive Breast Cancer Miguel Martín, Tadeusz Pieńkowski, John R. Mackey, New England Journal of Medicine	2005	950
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert, BMC Medical Genomics	2012	336
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz, JNCI Journal of the National Cancer Institute	2008	238
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial John R. Mackey, Miguel Martín, Tadeusz Pieńkowski, The Lancet Oncology Node-positive Breast CancerBreast OncologyOncologyAdjuvant DocetaxelBcirg 001	2012	221
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer Miguel Martín, Miguel Ángel Seguí, Antonio Antón, New England Journal of Medicine	2010	208
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen Miguel Martín, Aňa Lluch, Miguel Ángel Seguí, Annals of Oncology Breast OncologyBreast Cancer PatientsMedicineHealth-related QualityTac Regimen	2006	204
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression Maggie C.U. Cheang, Miguel Martín, Torsten O. Nielsen, The Oncologist	2015	194
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial Miguel Martín, Jan C. Brase, Lourdes Calvo, Breast Cancer Research	2014	160
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) Aňa Lluch, Carlos H. Barrios, Laura Torrecillas, Journal of Clinical Oncology	2019	143
Predicting response and survival in chemotherapy-treated triple-negative breast cancer Aleix Prat, Aňa Lluch, Joan Albanell, British Journal of Cancer	2014	110

Page 1